# Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

> **NCT03746522** · PHASE3 · COMPLETED · sponsor: **Rhythm Pharmaceuticals, Inc.** · enrollment: 52 (actual)

## Conditions studied

- Bardet Biedl Syndrome (BBS)
- Alström Syndrome (AS)

## Interventions

- **DRUG:** Setmelanotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03746522
- **Lead sponsor:** Rhythm Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-23
- **Primary completion:** 2020-11-16
- **Final completion:** 2021-03-08
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03746522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03746522, "Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03746522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*